In 0/10 OCR, 4/10 FTY and 3/10 NAT subjects, a detectable IFN-γ production was observed, but lower than the IFN-γ production previously detected in 5 PwMS on ocrelizumab with symptomatic COVID-19, analyzed elsewhere by our group (12) (Figure 3D). This evidence concerns the gene IFNG and COVID-19.